<p>令一些股东感到恼火的是，<strong>中进医疗</strong>（NASDAQ:ZJYL）在过去一个月的股价下跌了 27%，这延续了该公司的糟糕表现。对于任何长期股东来说，过去一个月结束了一年难以忘怀的经历，锁定了 74% 的股价下跌。</p>
<p>尽管价格大幅下跌，但中进医疗目前的市盈率（&#34;P/E&#34;）为 21.8 倍，可能仍在发出看跌信号，因为美国几乎一半的公司市盈率低于 18 倍，甚至低于 10 倍的市盈率也并不罕见。然而，市盈率可能高是有原因的，需要进一步调查以确定其合理性。</p>
<p>这项技术可能会取代计算机：发现 20 只正在努力使量子计算成为现实的股票。</p>
<p>例如，中进医疗最近盈利的下降值得深思。一个可能性是，市盈率高是因为投资者认为该公司在不久的将来仍会表现优于大盘。你真的希望如此，否则你就是在为没有特别理由的高价买单。</p>
<p>查看我们对中进医疗的最新分析</p>
<p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/asset/chart/1683020641-pe-multiple-vs-industry-1-dark-2/1763979992664?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://images.simplywall.st/asset/chart/1683020641-pe-multiple-vs-industry-1-dark-2/1763979992664"/></p>
<p>NasdaqCM:ZJYL 市盈率与行业比较 2025 年 11 月 24 日</p>
<p>尽管没有中进医疗的分析师预测，但请查看这个 <strong>免费的</strong> 数据丰富的可视化，看看该公司在盈利、收入和现金流方面的表现。</p>
<h2>中进医疗的增长趋势如何？</h2>
<p>中进医疗的市盈率对于一家预计将实现稳健增长的公司来说是典型的，重要的是，它的表现将优于市场。</p>
<p>首先回顾一下，公司的每股收益增长去年并不令人兴奋，出现了 39% 的令人失望的下降。这意味着在长期内，它的盈利也出现了下滑，过去三年每股收益总共下降了 99%。因此，不幸的是，我们必须承认该公司在这段时间内未能有效地增长盈利。</p>
<p>与市场相比，市场预计在未来 12 个月将实现 16% 的增长，而该公司基于最近中期盈利结果的下行势头则显得令人沮丧。</p>
<p>鉴于此，中进医疗的市盈率高于大多数其他公司令人担忧。显然，许多投资者对该公司的看法远比最近的情况更为乐观，并且不愿意以任何价格抛售他们的股票。只有最勇敢的人才会认为这些价格是可持续的，因为最近的盈利趋势的持续可能会对股价产生重大压力。</p>
<h2>关键要点</h2>
<p>如果说中进医疗的市盈率背后还有一些坚实的力量，尽管最近股价不佳。仅仅依靠市盈率来判断是否应该出售股票并不明智，但它可以作为公司未来前景的实用指南。</p>
<p>我们已经确定，中进医疗目前的市盈率远高于预期，因为其最近的盈利在中期内一直在下降。当我们看到盈利下滑并且表现不及市场预期时，我们怀疑股价面临下跌风险，从而导致高市盈率降低。如果最近的中期盈利趋势持续下去，将使股东的投资面临重大风险，并可能使潜在投资者支付过高的溢价。</p>
<p>你应该始终考虑风险。举个例子，我们发现了 <strong>中进医疗的 4 个警告信号</strong>，你应该注意，其中 1 个不容忽视。</p>
<p>如果这些 <strong>风险让你重新考虑对中进医疗的看法</strong>，请探索我们的高质量股票互动列表，以了解还有什么其他选择。</p>

中进医疗

<p>中进医疗国际有限公司（NASDAQ:ZJYL）的股价在过去一个月下跌了 27%，延续了一年来 74% 的下降趋势。尽管市盈率高达 21.8 倍，但公司的盈利却在下降，这引发了对未来股价稳定性的担忧。投资者依然持乐观态度，但高市盈率暗示如果盈利趋势持续，可能存在风险。股东应考虑这些风险，并探索其他投资选择</p>

<p>To the annoyance of some shareholders, <strong>Jin Medical International Ltd.</strong> (NASDAQ:ZJYL) shares are down a considerable 27% in the last month, which continues a horrid run for the company. For any long-term shareholders, the last month ends a year to forget by locking in a 74% share price decline.</p>
<div class="lb-trans"><p>令一些股东感到恼火的是，<strong>中进医疗</strong>（NASDAQ:ZJYL）在过去一个月的股价下跌了 27%，这延续了该公司的糟糕表现。对于任何长期股东来说，过去一个月结束了一年难以忘怀的经历，锁定了 74% 的股价下跌。</p>
</div><p>In spite of the heavy fall in price, Jin Medical International may still be sending bearish signals at the moment with its price-to-earnings (or &#34;P/E&#34;) ratio of 21.8x, since almost half of all companies in the United States have P/E ratios under 18x and even P/E's lower than 10x are not unusual. However, the P/E might be high for a reason and it requires further investigation to determine if it's justified.</p>
<div class="lb-trans"><p>尽管价格大幅下跌，但中进医疗目前的市盈率（&#34;P/E&#34;）为 21.8 倍，可能仍在发出看跌信号，因为美国几乎一半的公司市盈率低于 18 倍，甚至低于 10 倍的市盈率也并不罕见。然而，市盈率可能高是有原因的，需要进一步调查以确定其合理性。</p>
</div><p>This technology could replace computers: discover the 20 stocks are working to make quantum computing a reality.</p>
<div class="lb-trans"><p>这项技术可能会取代计算机：发现 20 只正在努力使量子计算成为现实的股票。</p>
</div><p>For instance, Jin Medical International's receding earnings in recent times would have to be some food for thought. One possibility is that the P/E is high because investors think the company will still do enough to outperform the broader market in the near future. You'd really hope so, otherwise you're paying a pretty hefty price for no particular reason.</p>
<div class="lb-trans"><p>例如，中进医疗最近盈利的下降值得深思。一个可能性是，市盈率高是因为投资者认为该公司在不久的将来仍会表现优于大盘。你真的希望如此，否则你就是在为没有特别理由的高价买单。</p>
</div><p>See our latest analysis for Jin Medical International</p>
<div class="lb-trans"><p>查看我们对中进医疗的最新分析</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/asset/chart/1683020641-pe-multiple-vs-industry-1-dark-2/1763979992664" alt="" original-src="https://images.simplywall.st/asset/chart/1683020641-pe-multiple-vs-industry-1-dark-2/1763979992664"/></p>
<p>NasdaqCM:ZJYL Price to Earnings Ratio vs Industry November 24th 2025</p>
<div class="lb-trans"><p>NasdaqCM:ZJYL 市盈率与行业比较 2025 年 11 月 24 日</p>
</div><p>Although there are no analyst estimates available for Jin Medical International, take a look at this <strong>free</strong> data-rich visualisation to see how the company stacks up on earnings, revenue and cash flow.</p>
<div class="lb-trans"><p>尽管没有中进医疗的分析师预测，但请查看这个 <strong>免费的</strong> 数据丰富的可视化，看看该公司在盈利、收入和现金流方面的表现。</p>
</div><h2>How Is Jin Medical International's Growth Trending?</h2>
<div class="lb-trans"><h2>中进医疗的增长趋势如何？</h2>
</div><p>Jin Medical International's P/E ratio would be typical for a company that's expected to deliver solid growth, and importantly, perform better than the market.</p>
<div class="lb-trans"><p>中进医疗的市盈率对于一家预计将实现稳健增长的公司来说是典型的，重要的是，它的表现将优于市场。</p>
</div><p>Taking a look back first, the company's earnings per share growth last year wasn't something to get excited about as it posted a disappointing decline of 39%. This means it has also seen a slide in earnings over the longer-term as EPS is down 99% in total over the last three years. So unfortunately, we have to acknowledge that the company has not done a great job of growing earnings over that time.</p>
<div class="lb-trans"><p>首先回顾一下，公司的每股收益增长去年并不令人兴奋，出现了 39% 的令人失望的下降。这意味着在长期内，它的盈利也出现了下滑，过去三年每股收益总共下降了 99%。因此，不幸的是，我们必须承认该公司在这段时间内未能有效地增长盈利。</p>
</div><p>Comparing that to the market, which is predicted to deliver 16% growth in the next 12 months, the company's downward momentum based on recent medium-term earnings results is a sobering picture.</p>
<div class="lb-trans"><p>与市场相比，市场预计在未来 12 个月将实现 16% 的增长，而该公司基于最近中期盈利结果的下行势头则显得令人沮丧。</p>
</div><p>In light of this, it's alarming that Jin Medical International's P/E sits above the majority of other companies. Apparently many investors in the company are way more bullish than recent times would indicate and aren't willing to let go of their stock at any price. Only the boldest would assume these prices are sustainable as a continuation of recent earnings trends is likely to weigh heavily on the share price eventually.</p>
<div class="lb-trans"><p>鉴于此，中进医疗的市盈率高于大多数其他公司令人担忧。显然，许多投资者对该公司的看法远比最近的情况更为乐观，并且不愿意以任何价格抛售他们的股票。只有最勇敢的人才会认为这些价格是可持续的，因为最近的盈利趋势的持续可能会对股价产生重大压力。</p>
</div><h2>The Key Takeaway</h2>
<div class="lb-trans"><h2>关键要点</h2>
</div><p>There's still some solid strength behind Jin Medical International's P/E, if not its share price lately. Using the price-to-earnings ratio alone to determine if you should sell your stock isn't sensible, however it can be a practical guide to the company's future prospects.</p>
<div class="lb-trans"><p>如果说中进医疗的市盈率背后还有一些坚实的力量，尽管最近股价不佳。仅仅依靠市盈率来判断是否应该出售股票并不明智，但它可以作为公司未来前景的实用指南。</p>
</div><p>We've established that Jin Medical International currently trades on a much higher than expected P/E since its recent earnings have been in decline over the medium-term. When we see earnings heading backwards and underperforming the market forecasts, we suspect the share price is at risk of declining, sending the high P/E lower. If recent medium-term earnings trends continue, it will place shareholders' investments at significant risk and potential investors in danger of paying an excessive premium.</p>
<div class="lb-trans"><p>我们已经确定，中进医疗目前的市盈率远高于预期，因为其最近的盈利在中期内一直在下降。当我们看到盈利下滑并且表现不及市场预期时，我们怀疑股价面临下跌风险，从而导致高市盈率降低。如果最近的中期盈利趋势持续下去，将使股东的投资面临重大风险，并可能使潜在投资者支付过高的溢价。</p>
</div><p>You should always think about risks. Case in point, we've spotted <strong>4 warning signs for Jin Medical International</strong> you should be aware of, and 1 of them shouldn't be ignored.</p>
<div class="lb-trans"><p>你应该始终考虑风险。举个例子，我们发现了 <strong>中进医疗的 4 个警告信号</strong>，你应该注意，其中 1 个不容忽视。</p>
</div><p>If these <strong>risks are making you reconsider your opinion on Jin Medical International</strong>, explore our interactive list of high quality stocks to get an idea of what else is out there.</p>
<div class="lb-trans"><p>如果这些 <strong>风险让你重新考虑对中进医疗的看法</strong>，请探索我们的高质量股票互动列表，以了解还有什么其他选择。</p>
</div>

由于股价遭遇 27% 的重挫，一些中进医疗国际有限公司（NASDAQ:ZJYL）的股东正在寻求退出